A new approach to control immune responses in the body
Official title: A modular cell therapy platform for controlling immunological tolerance
Funded at Stanford University · NIH-10899598 · Data updated 2026-11-12
This study is working on a new type of cell therapy that helps your immune system learn to ignore harmless substances, which could lead to better treatments for conditions like autoimmune diseases, cancer, and organ transplants, all while reducing side effects from current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 4, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $473,515 |
| NIH project number | 5DP2AI177915-02 |
| Project ID | NIH-10899598 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with autoimmune diseases, those undergoing organ transplantation, or patients with certain cancers.
✕Less likely to help
Patients with conditions that do not involve immune system dysregulation may not benefit from this research.
What this research studies
This research focuses on developing a modular cell therapy platform aimed at controlling immunological tolerance, which is crucial for preventing unwanted immune reactions against non-harmful substances. By leveraging advancements in T cell biology and synthetic biology, the project seeks to create therapies that can specifically target and regulate immune responses without broadly suppressing the immune system. This could lead to more effective treatments for autoimmune diseases, cancer, and organ transplantation, minimizing adverse effects associated with current therapies.
Why it matters
Potential benefit: If successful, this research could provide patients with safer and more effective treatments for autoimmune diseases and improve outcomes in organ transplantation.
How similar studies have gone: Previous research has shown promise in developing targeted immunotherapies, indicating potential for success in this novel approach.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Reticker-Flynn, Nathan Edward — Stanford University
- Study coordinator: Reticker-Flynn, Nathan Edward
Related research
Other NIH-funded projects on the same topics.
-
Multimodal AI to predict CAR-T patient response and guide safer, smarter cell design
A Stanford team is building AI tools that use patient and CAR-T cell data to predict how well a CAR-T therapy will work and what design changes might boost effectiveness and safety for people with cancer.
-
Community-driven model to reduce overdose deaths through smarter resource use
A Stanford-led project uses a data-driven model to help counties pick the best ways to prevent opioid and stimulant overdoses and save lives.
-
Center for Dissemination and Implementation at Stanford: Research Core
A Stanford-based program is advancing how evidence-based addiction treatments are implemented across settings to help people with substance use disorders receive better care.
-
Center for Dissemination and Implementation At Stanford (C-DIAS)
A center-based program at Stanford aims to speed people who need addiction treatments to get evidence-based care.
-
Mitochondrial structure and neuron health in Alzheimer's and ALS
This grant studies how mitochondrial cristae structure in neurons is controlled and how its disruption may contribute to diseases like Alzheimer's and ALS.
-
Pediatric EMS seizures: simpler age-based midazolam dosing
A nationwide trial at EMS agencies tests whether using fixed, age-based dosing of midazolam for seizures in children improves treatment speed and safety.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.